TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
DNA

Ginkgo Bioworks Holdings

Healthcare · Biotechnology

8.00$ +1.3% vs. previous close Closing price · As of: Sep 21, 2026

Statements

Income Statement

Ginkgo Bioworks Holdings (DNA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 20 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement DNA
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
55 35 38 56 89 44 48 50 39 33 19 20 112
6.9 6.6 9.2 14 10.0 9.6 12 15 13 -8.2 16 1.7 22
49 28 29 42 79 34 36 35 26 42 3.6 18 90
157 117 136 134 77 76 71 53 69 50 50 46 216
82 89 70 66 52 57 49 43 45 46 38 31 160
335 206 207 265 134 138 125 100 116 112 75 77 380
-286 -178 -178 -223 -55 -104 -89 -66 -90 -71 -71 -59 -291
0.1 0.1
-303 -212 -166 -217 -57 -108 -91 -61 -81 -81 -76 -57 -295
0.0 -0.2 0.0 0.2 -0.4 -0.3 0.1 -0.3 0.0 -0.6 -0.1 0.1 -0.6
-303 -212 -166 -217 -56 -108 -91 -60 -81 -81 -83 -47 -291
-169 -289 -153 -141 -35 -143 -68 -46 -67 -35 -63 -44 -209

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?